These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 10415871

  • 1. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
    Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, Ruggeri BA.
    Ann N Y Acad Sci; 1999 Jun 30; 880():252-62. PubMed ID: 10415871
    [Abstract] [Full Text] [Related]

  • 2. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA.
    Clin Cancer Res; 1999 Aug 30; 5(8):2205-12. PubMed ID: 10473107
    [Abstract] [Full Text] [Related]

  • 3. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.
    Clin Cancer Res; 1998 Aug 15; 4(8):1887-98. PubMed ID: 9717816
    [Abstract] [Full Text] [Related]

  • 7. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
    Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.
    Int J Cancer; 1997 Aug 07; 72(4):673-9. PubMed ID: 9259409
    [Abstract] [Full Text] [Related]

  • 8. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, Wang P, Ma X, Kroemer G, Bartlett DL, Billiar TR, Lotze MT, Zeh HJ, Kang R, Tang D.
    Gastroenterology; 2018 Apr 07; 154(5):1480-1493. PubMed ID: 29248440
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
    Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM.
    Med Pediatr Oncol; 2001 Jan 07; 36(1):181-4. PubMed ID: 11464878
    [Abstract] [Full Text] [Related]

  • 11. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
    Sano M, Ichimaru Y, Kurita M, Hayashi E, Homma T, Saito H, Masuda S, Nemoto N, Hemmi A, Suzuki T, Miyairi S, Hao H.
    Cancer Lett; 2017 Jul 01; 397():72-82. PubMed ID: 28347789
    [Abstract] [Full Text] [Related]

  • 12. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD.
    Cancer Res; 2003 Sep 01; 63(17):5559-63. PubMed ID: 14500395
    [Abstract] [Full Text] [Related]

  • 13. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
    Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT.
    Cancer Res; 2002 Feb 15; 62(4):986-9. PubMed ID: 11861369
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
    Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM.
    Clin Cancer Res; 1999 Nov 15; 5(11):3594-602. PubMed ID: 10589776
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER.
    Biomaterials; 2016 Jul 15; 93():71-82. PubMed ID: 27082874
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M.
    Int J Oncol; 2007 Jan 15; 30(1):193-200. PubMed ID: 17143529
    [Abstract] [Full Text] [Related]

  • 20. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.